Cingulate's CTx-1301 Secures Key Patents, NDA Progresses to May PDUFA, $12M Private Placement Closed
Summary
Cingulate Inc. announced a series of significant operational milestones alongside its Q4 and full-year 2025 financial results. Most notably, the company secured a U.S. Patent Notice of Allowance and received European patent grants for its lead ADHD drug candidate, CTx-1301, extending intellectual property protection through May 2042. The FDA has accepted the New Drug Application (NDA) for CTx-1301 for review, setting a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026, despite some requests for additional manufacturing and CMC information. Furthermore, Cingulate successfully closed a $12 million private placement, bolstering its financial foundation, and appointed a Chief Commercial Officer to advance commercial readiness. These developments, particularly the strengthened patent estate and clear regulatory pathway for CTx-1301, are highly material for the biopharmaceutical company, providing significant de-risking and a clear near-term catalyst. Investors will now focus on the FDA's decision regarding CTx-1301 by the PDUFA date.
At the time of this announcement, CING was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.5M. The 52-week trading range was $3.20 to $11.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.